Recce Pharmaceuticals up 6% on new antibiotic production milestone
Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch of its new antibiotic RECCE 327 (R327) under Good Manufacturing Practises (GMP) standards.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
OCA | Ann: FY2024 Market Update | 15/04/24 | 0 | 95 | |||
|
|||||||
OCA | Ann: SPH Notice - Forsyth Barr Investment Management Limited | 03/04/24 | 0 | 71 | |||
|
|||||||
OCA | Ann: Oceania leadership transition | 26/02/24 | 0 | 101 | |||
|
|||||||
OCA | Ann: SPH Notice - ANZ New Zealand Investments Limited | 23/02/24 | 0 | 89 | |||
|
|||||||
OCA | Ann: Oceania Healthcare Limited - Change of contact details | 16/02/24 | 0 | 119 | |||
|
|||||||
OCA | Ann: Appointment of Group General Counsel | 18/12/23 | 0 | 92 | |||
|
|||||||
OCA | Ann: D&O Ongoing Disclosure Notice | 07/12/23 | 0 | 122 | |||
|
|||||||
OCA | Ann: SPH Notice - ANZ New Zealand Investments Limited | 06/12/23 | 0 | 81 | |||
|
See All Discussions